[144] Beta Bionics, Inc. SEC Filing

Rhea-AI Filing Summary

Beta Bionics, Inc. Form 144 shows a proposed sale of 4,982 common shares through Merrill Lynch on 10/03/2025 with an aggregate market value of $108,076.24. The filing identifies prior insider sales by Stephen Feider in the past three months, including a 15,018-share trade on 10/01/2025 that generated $311,836.91 and other sales dated 09/08/2025, 09/05/2025, 08/22/2025, and 08/19/2025. The securities to be sold were acquired via stock options on 10/03/2025 and the filing indicates payment was made in cash on 10/01/2025. The seller represents there is no undisclosed material adverse information. The filing supplies transaction details but does not include the issuer's SEC file number, issuer address, or the filer CIK.

Positive

• Proposed sale is clearly identified: 4,982 shares for $108,076.24 on 10/03/2025
• Broker is specified as Merrill Lynch, providing an execution venue
• Acquisition method is disclosed as stock options, and payment method shown as cash

Negative

• Multiple recent insider sales by Stephen Feider, including 15,018 shares on 10/01/2025
• Filing content omits issuer identifiers (CIK and SEC file number) and issuer address in the provided extract
• Limited context—the filing contains no explanation for the sales or any issuer operational information

Insights

Insider Transactions Analyst

Insider plans to sell 4,982 shares; recent large disposals occurred.

The Form 144 discloses a proposed sale of 4,982 common shares for $108,076.24 on 10/03/2025 through Merrill Lynch. The filing also lists multiple recent sales by Stephen Feider, including a 15,018-share sale on 10/01/2025 raising $311,836.91. These are explicit, non-speculative facts from the notice.

This pattern shows ongoing sales by the same person within a short window; that is relevant to investors tracking insider liquidity but is descriptive only and contains no explanation for motives.

Securities Compliance Officer

Filing includes required representations and identifies acquisition method as stock options.

The form states the securities were acquired by stock options on 10/03/2025 and payment was in cash on 10/01/2025, and it includes the standard signature representation about nondisclosure of material adverse information. The broker is named as Merrill Lynch.

The notice omits several issuer administrative fields (CIK, SEC file number, issuer address) in the provided content, which limits completeness for compliance tracking.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 6002 El Tordo 2nd FL PO Box 7297 Rancho Santa Fe CA 92067	4982	108076.24	43470125	10/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/03/2025	Stock Options	issuer			4982	10/01/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Stephen Feider 11 HUGHES Irvine CA 92618	Common	10/01/2025	15018	311836.91
Stephen Feider 11 HUGHES Irvine CA 92618	Common	09/08/2025	9900	209152.15
Stephen Feider 11 HUGHES Irvine CA 92618	Common	09/05/2025	100	2100
Stephen Feider 11 HUGHES Irvine CA 92618	Common	08/22/2025	4413	75082.65
Stephen Feider 11 HUGHES Irvine CA 92618	Common	08/19/2025	5587	1497

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Beta Bionics (BBNX) Form 144 report?

The filing reports a proposed sale of 4,982 common shares through Merrill Lynch on 10/03/2025 with an aggregate market value of $108,076.24.

Who is the seller listed on the Form 144 for BBNX?

The recent sales listed in the filing were made by Stephen Feider; he appears as the seller for multiple transactions in Aug–Oct 2025.

Were there recent insider sales before the proposed 10/03/2025 sale?

Yes. The filing lists a 15,018-share sale on 10/01/2025 with gross proceeds of $311,836.91, and other sales on 09/08/2025, 09/05/2025, 08/22/2025, and 08/19/2025.

How were the securities being sold originally acquired?

The securities were acquired via stock options on 10/03/2025 according to the filing, with payment in cash on 10/01/2025.

Does the filing state there is undisclosed material information?

The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.